Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma

Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara, Masashi Doi, Mamoru Shiga

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Pranlukast hydrate (CAS 103177-37-3, ONO-1078) was administered to 20 patients with bronchial asthma, and examined the effects of this agent on serum eosinophil cationic protein (ECP) levels and peripheral blood eosinophil counts. The mean serum ECP level in the group comprised of patients with bronchial asthma was significantly higher than that in the control group comprised of healthy adults. In responders in whom improvement in asthmatic symptoms was observed, serum ECP levels were significantly decreased compared to the pretreatment values 4 weeks after commencement of pranlukast hydrate administration. However, there were no changes in non- responders. There was no correlation between serum ECP level and peripheral blood eosinophil count before administration of pranlukast hydrate. However, there was a correlation 4 weeks after administration was started. Iris suggested that pranlukast hydrate inhibits eosinophilic activity in patients with bronchial asthma.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Volume49
Issue number1
DOIs
Publication statusPublished - 1999

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma'. Together they form a unique fingerprint.

Cite this